This week, the European Union announced the approval of the first Ebola vaccine. The disease is transmitted by a virus and became famous in 2014, when an epidemic occurred that killed thousands in Africa.
The vaccine was named Ervebo and has been waiting for authorization since last October. At the time a committee was organized by the European Medicines Agency (EMA) to request its conditional marketing, due to a need for untreated pathology so far.
The vaccine was previously applied to people in the Democratic Republic of Congo. According to preliminary statistics, less than 3% of about 100,000 vaccinated – among the most likely to develop the disease – did not get the disease.
In contrast, the World Health Organization (WHO) stated last month that licensed doses of Everbo will only be available in the middle of next year. Until then, only the test vaccine will be accessible.
To date, there is only approval to take Everbo for patients who are over 18 years old. It has not yet been announced whether the age range could be extended in the future when the final version is released.
Remember that in August this year, another vaccine promised to prevent the allergy of humans to cats. Biotechnology company HypoPet AG, University of Zurich, Switzerland, recently released a new vaccine that prevents the transmission of the fel d1 allergen virus from cats to humans, good news for those who did not have contact or would forgo this pet by have an allergy.
It is very common nowadays to see people who are allergic to cats and in most cases are those who have the desire to raise the feline but need to refrain from doing so as not to cause serious health damage as some allergic people may even come to death.
However, those who do not want to give up having a pet to call their own can choose to get the vaccine that prevents the side effects of this constant living. But it does not have a 100% effective result because the cat continues to have the causative agent of allergy in its body.
